{
    "clinical_study": {
        "@rank": "21788", 
        "arm_group": [
            {
                "arm_group_label": "Loteprednol etabonate + Restasis", 
                "arm_group_type": "Active Comparator", 
                "description": "Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days"
            }, 
            {
                "arm_group_label": "Artificial Tears + Restasis", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Artificial Tears, BID 30 days Restasis, BID 45 days"
            }
        ], 
        "brief_summary": {
            "textblock": "A pilot study to evaluate the impact of Lotemax\u00ae Gel (loteprednol etabonate ophthalmic gel\n      0.5%) on the initiation of Restasis\u00ae (cyclosporine ophthalmic emulsion 0.05%) therapy in\n      subjects with dry eye."
        }, 
        "brief_title": "A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis\u00ae", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye Disease", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes", 
                "Eye Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Provide written informed consent prior to any study-related procedures and provide\n             Health Insurance Portability and Accountability Act (HIPAA) authorization.\n\n          2. Are between the ages of 21 and 80 inclusive.\n\n          3. Have not worn contact lenses for at least 1 month prior to the study and agrees not\n             to wear contact lenses during the study.\n\n          4. Have been on stable oral medications for 1 month prior to the study.\n\n          5. Are in generally good and stable overall health.\n\n          6. Are a woman of child bearing potential (WOCBP) who is not pregnant or lactating and\n             not sexually active (i.e. abstinent) at Visit 1 and willing to remain so through\n             Visit 4. Alternatively, a WOCBP who is not abstinent must have been using an\n             acceptable method of birth control for at least 4 weeks prior to Visit 1 and\n             throughout the study.\n\n          7. Are women who have undergone one of the following sterilization procedures at least 1\n             month prior to Visit 1:\n\n               1. Bilateral tubal ligation\n\n               2. Hysterectomy\n\n               3. Hysterectomy with unilateral or bilateral oophorectomy.\n\n               4. Bilateral oophorectomy\n\n          8. Are likely to comply with the eye drop regime, study guidelines, and study visits.\n\n        Exclusion Criteria:\n\n          1. Have a history of Stevens-Johnson Syndrome or ocular pemphigoid.\n\n          2. Have had punctual plugs inserted or removed; or punctual cautery 3 months prior to\n             Visit 1/Screening and Baseline Visit and throughout the study.\n\n          3. Have had intra-ocular surgery within 6 months prior to the Visit 1/Screening and\n             Baseline Visit.\n\n          4. Have a history of liver disease.\n\n          5. Be pregnant or lactating.\n\n          6. Have severe clinical vitamin deficiencies or a history of vitamin overdose.\n\n          7. Have a highly variable vitamin intake.\n\n          8. Wear contact lenses.\n\n          9. Have unstable use of systemic or topical medications known to create dry eye.\n\n         10. Have corneal pathology, which could, of itself, cause an ocular surface disorder.\n\n         11. Have used glaucoma medications, topical or oral within 30 days of Visit 1/Screening\n             and Baseline Visit.\n\n         12. Have unstable diabetes mellitus.\n\n         13. Have an allergy or sensitivity to Lotemax\u00ae Gel, Restasis\u00ae, or non-preservative\n             artificial tears.\n\n         14. Have used topical steroids or Restasis\u00ae within 1 month prior to the Screening and\n             Baseline Visit and throughout the study, except the study medication provided per the\n             protocol.\n\n         15. Have a condition for which steroid use would be contraindicated (e.g. viral\n             infection).\n\n         16. Use other topical ocular agents other than tear replacements within 1 week prior to\n             the Screening and Baseline Visit and throughout the study.\n\n         17. Have been exposed to an investigational drug within the preceding 30 days.\n\n         18. In the opinion of the investigator or study coordinator, be unwilling or unable to\n             comply with the study protocol or unable to successfully instill eye drops."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028312", 
            "org_study_id": "CEI.HER-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Loteprednol etabonate + Restasis", 
                "intervention_name": "Loteprednol etabonate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Artificial Tears + Restasis", 
                "intervention_name": "Artificial Tears", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Loteprednol etabonate + Restasis", 
                    "Artificial Tears + Restasis"
                ], 
                "intervention_name": "Restasis", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Loteprednol etabonate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Dry Eye", 
        "lastchanged_date": "January 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Rancho Cordova", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95670"
                    }, 
                    "name": "Martel Eye Medical Group"
                }, 
                "investigator": {
                    "last_name": "Joseph Martel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edgewood", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "41017"
                    }, 
                    "name": "Cincinnati Eye Institute"
                }, 
                "investigator": {
                    "last_name": "Edward Holland, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stillwater", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55082"
                    }, 
                    "name": "Associated Eye Care"
                }, 
                "investigator": {
                    "last_name": "Stephen Lane, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "kristin@lexitaspharma.com", 
            "last_name": "Kristin Williams"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Fluorescein corneal staining scores", 
            "safety_issue": "No", 
            "time_frame": "60 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028312"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Holprovision", 
            "investigator_full_name": "Edward Holland, MD", 
            "investigator_title": "Sponsor-Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Lissamine green conjunctival staining", 
            "safety_issue": "No", 
            "time_frame": "60 Days"
        }, 
        "source": "Holprovision", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Edward Holland, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}